Primary anatomical site, adjuvant therapy, and other prognostic variables for dedifferentiated liposarcoma

Jonathan Gootee, Sarah Aurit, Christina Curtin, Peter T. Silberstein

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Dedifferentiated liposarcoma (DDLPS) is a high-grade, clinically aggressive tumor associated with low survival probabilities. Prognostic variables for DDLPS have not been previously reported in a large patient population. Methods: A total of 3573 patients with primary DDLPS were analyzed from the National Cancer Data Base (NCDB). The 5- and 10-year survival probabilities were calculated, and the groups were compared using log-rank comparisons and multivariable Cox hazard regression analysis. Median survival was also calculated. Results: Males comprised 65% of the cohort, the median age at diagnosis was 64 years of age, and 65.4% of the patients were between 51 and 75 years of age. The most common site for primary tumors is the retroperitoneum or abdomen (59.5%). Head or neck tumors had the best 5-year outcomes (86.4%) followed by extremities (67.1%), pelvis (65.8%), thorax or trunk (58.9%), and finally retroperitoneum or abdomen (42.6%). Best outcomes were noted in the 26- to 50-year-old age group (5-year survival:66.8%), < 10 cm size (5-year survival:66.1%), FNCLCC grade 1 (5-year survival:69.2%), and stage II disease (5-year survival:66.7%). Radiation therapy yielded the best 5-year and 10-year survival probabilities of 59% and 39.3%, respectively. Out of all the adjuvant therapies, the use of radiation resulted in the best 5-year survival of 63.4%. Conclusion: In the largest and most comprehensive study to date on DDLPS, major findings include primary site as a significant prognostic variable with age at presentation, sex, tumor stage, and type of adjuvant therapy significantly impacting overall survival.

Original languageEnglish (US)
JournalJournal of Cancer Research and Clinical Oncology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Liposarcoma
Survival
Therapeutics
Neoplasms
Abdomen
Radiotherapy
Pelvis
Neck
Thorax
Extremities
Age Groups
Head
Regression Analysis
Databases

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Primary anatomical site, adjuvant therapy, and other prognostic variables for dedifferentiated liposarcoma. / Gootee, Jonathan; Aurit, Sarah; Curtin, Christina; Silberstein, Peter T.

In: Journal of Cancer Research and Clinical Oncology, 01.01.2018.

Research output: Contribution to journalArticle

@article{1ed58aab3ff845bea18720d5999f8b62,
title = "Primary anatomical site, adjuvant therapy, and other prognostic variables for dedifferentiated liposarcoma",
abstract = "Background: Dedifferentiated liposarcoma (DDLPS) is a high-grade, clinically aggressive tumor associated with low survival probabilities. Prognostic variables for DDLPS have not been previously reported in a large patient population. Methods: A total of 3573 patients with primary DDLPS were analyzed from the National Cancer Data Base (NCDB). The 5- and 10-year survival probabilities were calculated, and the groups were compared using log-rank comparisons and multivariable Cox hazard regression analysis. Median survival was also calculated. Results: Males comprised 65{\%} of the cohort, the median age at diagnosis was 64 years of age, and 65.4{\%} of the patients were between 51 and 75 years of age. The most common site for primary tumors is the retroperitoneum or abdomen (59.5{\%}). Head or neck tumors had the best 5-year outcomes (86.4{\%}) followed by extremities (67.1{\%}), pelvis (65.8{\%}), thorax or trunk (58.9{\%}), and finally retroperitoneum or abdomen (42.6{\%}). Best outcomes were noted in the 26- to 50-year-old age group (5-year survival:66.8{\%}), < 10 cm size (5-year survival:66.1{\%}), FNCLCC grade 1 (5-year survival:69.2{\%}), and stage II disease (5-year survival:66.7{\%}). Radiation therapy yielded the best 5-year and 10-year survival probabilities of 59{\%} and 39.3{\%}, respectively. Out of all the adjuvant therapies, the use of radiation resulted in the best 5-year survival of 63.4{\%}. Conclusion: In the largest and most comprehensive study to date on DDLPS, major findings include primary site as a significant prognostic variable with age at presentation, sex, tumor stage, and type of adjuvant therapy significantly impacting overall survival.",
author = "Jonathan Gootee and Sarah Aurit and Christina Curtin and Silberstein, {Peter T.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00432-018-2777-3",
language = "English (US)",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Primary anatomical site, adjuvant therapy, and other prognostic variables for dedifferentiated liposarcoma

AU - Gootee, Jonathan

AU - Aurit, Sarah

AU - Curtin, Christina

AU - Silberstein, Peter T.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Dedifferentiated liposarcoma (DDLPS) is a high-grade, clinically aggressive tumor associated with low survival probabilities. Prognostic variables for DDLPS have not been previously reported in a large patient population. Methods: A total of 3573 patients with primary DDLPS were analyzed from the National Cancer Data Base (NCDB). The 5- and 10-year survival probabilities were calculated, and the groups were compared using log-rank comparisons and multivariable Cox hazard regression analysis. Median survival was also calculated. Results: Males comprised 65% of the cohort, the median age at diagnosis was 64 years of age, and 65.4% of the patients were between 51 and 75 years of age. The most common site for primary tumors is the retroperitoneum or abdomen (59.5%). Head or neck tumors had the best 5-year outcomes (86.4%) followed by extremities (67.1%), pelvis (65.8%), thorax or trunk (58.9%), and finally retroperitoneum or abdomen (42.6%). Best outcomes were noted in the 26- to 50-year-old age group (5-year survival:66.8%), < 10 cm size (5-year survival:66.1%), FNCLCC grade 1 (5-year survival:69.2%), and stage II disease (5-year survival:66.7%). Radiation therapy yielded the best 5-year and 10-year survival probabilities of 59% and 39.3%, respectively. Out of all the adjuvant therapies, the use of radiation resulted in the best 5-year survival of 63.4%. Conclusion: In the largest and most comprehensive study to date on DDLPS, major findings include primary site as a significant prognostic variable with age at presentation, sex, tumor stage, and type of adjuvant therapy significantly impacting overall survival.

AB - Background: Dedifferentiated liposarcoma (DDLPS) is a high-grade, clinically aggressive tumor associated with low survival probabilities. Prognostic variables for DDLPS have not been previously reported in a large patient population. Methods: A total of 3573 patients with primary DDLPS were analyzed from the National Cancer Data Base (NCDB). The 5- and 10-year survival probabilities were calculated, and the groups were compared using log-rank comparisons and multivariable Cox hazard regression analysis. Median survival was also calculated. Results: Males comprised 65% of the cohort, the median age at diagnosis was 64 years of age, and 65.4% of the patients were between 51 and 75 years of age. The most common site for primary tumors is the retroperitoneum or abdomen (59.5%). Head or neck tumors had the best 5-year outcomes (86.4%) followed by extremities (67.1%), pelvis (65.8%), thorax or trunk (58.9%), and finally retroperitoneum or abdomen (42.6%). Best outcomes were noted in the 26- to 50-year-old age group (5-year survival:66.8%), < 10 cm size (5-year survival:66.1%), FNCLCC grade 1 (5-year survival:69.2%), and stage II disease (5-year survival:66.7%). Radiation therapy yielded the best 5-year and 10-year survival probabilities of 59% and 39.3%, respectively. Out of all the adjuvant therapies, the use of radiation resulted in the best 5-year survival of 63.4%. Conclusion: In the largest and most comprehensive study to date on DDLPS, major findings include primary site as a significant prognostic variable with age at presentation, sex, tumor stage, and type of adjuvant therapy significantly impacting overall survival.

UR - http://www.scopus.com/inward/record.url?scp=85055958420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055958420&partnerID=8YFLogxK

U2 - 10.1007/s00432-018-2777-3

DO - 10.1007/s00432-018-2777-3

M3 - Article

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

ER -